Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)

Inclusion Criteria: * Phase 1: * Age \>18 years * Calculated creatinine clearance \>70 mL/min/1.73 m2 (measured within 3 months) * Written informed consent Phase 2: * Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG) * Ability and willingness to provide informed consent * Willing to receive protocol-specified lumbar punctures Exclusion Criteria: * Phase 1: * Symptomatic Current illness * Known significant, untreated health problem * Inability to take enteral medicine * Pregnant or breast feeding * Receiving amphotericin B therapy in past 90 days * Phase 2: * Presenting Glasgow Coma Scale (GCS) \< 15 * Received 3 or more doses of IV amphotericin therapy within last 30 days * Inability to take enteral (oral or nasogastric) medicine * Cannot or unlikely to attend regular clinic visits * Pregnancy or breastfeeding * Receiving chemotherapy or corticosteroids * Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS) * Recent initiation of HIV therapy or ART class switch (within 2 weeks)